Accès libre

Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients

Blaž Matija Geršak
Blaž Matija Geršak
, 
Andreja Kukec
Andreja Kukec
, 
Henning Steen
Henning Steen
, 
Moritz Montenbruck
Moritz Montenbruck
, 
Maja Šoštarič
Maja Šoštarič
, 
Arne Kristian Schwarz
Arne Kristian Schwarz
, 
Sebastian Esch
Sebastian Esch
, 
Sebastian Kelle
Sebastian Kelle
, 
Sorin Giusca
Sorin Giusca
, 
Grigorios Korosoglou
Grigorios Korosoglou
, 
Pia Wülfing
Pia Wülfing
, 
Susan Dent
Susan Dent
 et 
Daniel Lenihan
Daniel Lenihan
   | 20 oct. 2021
Slovenian Journal of Public Health's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Article Category: Original scientific article
Publié en ligne: 20 oct. 2021
Pages: 199 - 209
Reçu: 09 mars 2021
Accepté: 31 mars 2021
DOI: https://doi.org/10.2478/sjph-2021-0028
Mots clés
© 2021 National Institute of Public Health, Slovenia, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 2

EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 3

EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 4

SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 5

SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 6

SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 7

SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 8

SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 9

SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
eISSN:
1854-2476
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, Hygiene and Environmental Medicine
RSS Feed de la revue